Bufalin: a potential drug for regulating EGFR-TKIs resistance in lung cancer via the EGFR-PI3K/Akt-mTOR signaling

Authors

Institutions

Publication Details

Journal
Translational Cancer Research
Published
2025-12-01
DOI
https://doi.org/10.21037/tcr-2025-1217
Primary Topic
PI3K/AKT/mTOR signaling in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Bufalin: a potential drug for regulating EGFR-TKIs resistance in lung cancer via the EGFR-PI3K/Akt-mTOR signaling

Xiaozhen ZHAO, Longke Dong, Yabin Gong, Ruifang Cui et al.
Translational Cancer Research
PI3K/AKT/mTOR signaling in cancer
article

Bufalin: a potential drug for regulating EGFR-TKIs resistance in lung cancer via the EGFR-PI3K/Akt-mTOR signaling

Xiaozhen ZHAO, Longke Dong, Yabin Gong, Ruifang Cui, Chang Liu, Yueqin Bai, Qingpeng Deng
article en

Abstract

No abstract available for this paper.
Translational Cancer ResearchVol. 14(12)
Shanghai University of Traditional Chinese Medicine (CN), Longhua Hospital Shanghai University of Traditional Chinese Medicine (CN), Yueyang Hospital (CN), Baoji City Central Hospital (CN)
Good health and well-being
Openalex Percentile: Top 35%
PI3K/AKT/mTOR signaling in cancer
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.